Jack Khattar Sells 29,513 Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) Stock

Key Points

• Jack Khattar, CEO of Supernus Pharmaceuticals, sold 29,513 shares at an average price of $47.23, totaling approximately $1.39 million, reducing his ownership by 2.52%.
• Supernus Pharmaceuticals' stock price has increased by 0.6%, currently trading at $47.10, with a market capitalization of $2.64 billion.
• Analysts have given a consensus rating of "Buy" for Supernus Pharmaceuticals, with price targets ranging from $40.00 to $46.00.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) CEO Jack Khattar sold 29,513 shares of the firm's stock in a transaction dated Tuesday, September 23rd. The shares were sold at an average price of $47.23, for a total transaction of $1,393,898.99. Following the completion of the sale, the chief executive officer owned 1,140,883 shares in the company, valued at $53,883,904.09. This represents a 2.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Supernus Pharmaceuticals Stock Up 0.6%

Shares of Supernus Pharmaceuticals stock traded up $0.27 during midday trading on Wednesday, hitting $47.10. The company had a trading volume of 459,628 shares, compared to its average volume of 645,302. The stock has a market cap of $2.64 billion, a price-to-earnings ratio of 40.96 and a beta of 0.79. The company has a fifty day simple moving average of $41.20 and a 200 day simple moving average of $35.27. Supernus Pharmaceuticals, Inc. has a 12-month low of $29.16 and a 12-month high of $47.65.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Wall Street Zen raised shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Piper Sandler increased their price target on shares of Supernus Pharmaceuticals from $36.00 to $40.00 and gave the stock a "neutral" rating in a report on Friday, August 29th. Zacks Research upgraded shares of Supernus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Wednesday, September 17th. Finally, Cantor Fitzgerald raised their price objective on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $43.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SUPN. Financial Management Professionals Inc. purchased a new position in Supernus Pharmaceuticals in the 1st quarter valued at $30,000. Versant Capital Management Inc increased its holdings in shares of Supernus Pharmaceuticals by 6,931.3% in the first quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company's stock valued at $37,000 after purchasing an additional 1,109 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Supernus Pharmaceuticals in the first quarter valued at approximately $41,000. GF Fund Management CO. LTD. purchased a new position in Supernus Pharmaceuticals during the fourth quarter worth approximately $42,000. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new position in Supernus Pharmaceuticals during the first quarter worth $46,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.